Naslov
Platelet and serum BDNF level and response to rTMS treatment ; A nested prospective cohort study in Croatia

Autori
Ruljančić, Nedjeljka ; Filipčić, Igor ; Šimunović Filipčić, Ivona ; Gajšak, Tomislav ; Milovac, Željko ; Sučić, Strahimir ; Zečević Penić, Sandra ; Bajić, Žarko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Clin Chem Lab Med 2018 ; 56(11):eA203-eA359. / - , 2018, EA340-eA340

Skup
5th EFLM-UEMS European Joint Congress in Laboratory Medicine

Mjesto i datum
Antalya, Turska, 10.10.2018. - 13.10.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Platelet BDNF ; Transcranical magnetic stimulation ; Major depressive disorder

Sažetak
Purpose: Transcranial magnetic stimulation (TMS) is indirect and non-invasive methods used to induce an electric current in the motor cortex generating a magnetic field that passes through the scalp. Several research were shown higher serum or plasma BDNF level after rTMS treatment but in some there were no connection between serum or plasma BDNF and rTMS treatment in depressed patients. The objective of this study was to examine whether the outcome of rTMS treatment of MDD (major depressive disorders) can be predicted by platelet or serum BDNF concentration levels. Materials and Methods: This prospective cohort study was nested within the randomized controlled trial conducted at Psychiatric Hospital Sveti Ivan, Zagreb, Croatia during 2017, on the sample of 15 patients, median (IQR) age of 56 (46-63), male 10/female 5 (Table 1.). Outcome was the change in Hamilton Depression Scale (HAM-D17) after four weeks treatment with rTMS. The serum and platelet BDNF concentration has been determined by enzyme- immunoassay method. The content of platelet BDNF is referred to ng/ 109 platelets. The main analysis was done by robust regression. Results: After four weeks treatment with rTMS, platelet and serum BDNF concentrations were not significantly changed (Table 2). Baseline concentration of platelet BDNF was univariately significantly associated with the absolute change of HAM-D17 result adjusted for the baseline HAM-D17 values (R2=0.32 ; p=0.045). This association strengthened after the adjustments for age and sex (b=0.51, β=0.95, t=3.89, p=0.006). Conclusions: Platelet BDNF baseline concentration is a promising biomarker of TMS efficacy in treatment of MDD.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA